Rustem Gafanov

TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.

TL;DR: With extended study follow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior clinical outcomes over sunit inib, and these results continue to support the first-line treatment with pembroizumAB plus ax itinib as the standard of care of advanced renal cell carcinoma.

TL;DR: In this paper, the authors assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.

TL;DR: PURPOSEPembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types The phase II KEYNOTE-427 study evaluated efficacy as discussed by the authors.

TL;DR: In this paper, a randomized, double-blind, phase 3 trial at 200 sites across 26 countries or regions was conducted to compare ipatasertib plus abiraterone with placebo plus abaraterone in patients with previously untreated mCRPC with or without tumour PTEN loss.